The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Quantitation of Doxorubicin Uptake, Efflux, and Modulation of Multidrug Resistance (MDR) in MDR Human Cancer Cells
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bradford, M. M. (1976) · Analytical Biochemistry · doi:10.1016/0003-2697(76)90527-3 · Cited by 255,302
Multidrug resistance in cancer: role of ATP–dependent transporters
Gottesman, M. M., Fojo, T., & Bates, S. E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc706 · Cited by 5,536
Thomas, H., & Coley, H. M. (2003) · Cancer Control · doi:10.1177/107327480301000207 · Cited by 931
Multidrug resistance transporters and modulation
Tan, B., Piwnica-Worms, D., & Ratner, L. (2000) · Current Opinion in Oncology · doi:10.1097/00001622-200009000-00011 · Cited by 384
Pusztai, L., Wagner, P., Ibrahim, N., Rivera, E., Theriault, R., Booser, D., Symmans, F. W., Wong, F., Blumenschein, G., Fleming, D. R., et al. (2005) · Cancer · doi:10.1002/cncr.21227 · Cited by 302
ATP binding cassette transporters and drug resistance in breast cancer.
Leonessa, F., & Clarke, R. (2003) · Endocrine-related cancer · doi:10.1677/erc.0.0100043 · Cited by 259
Cyclosporin A Is a Broad-Spectrum Multidrug Resistance Modulator
Qadir, M., O'Loughlin, K. L., Fricke, S. M., Williamson, N. A., Greco, W. R., Minderman, H., & Baer, M. R. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1725 · Cited by 236
Clinical trials of p-glycoprotein reversal in solid tumours
Ferry, D. R., Traunecker, H., & Kerr, D. J. (1996) · European Journal of Cancer · doi:10.1016/0959-8049(96)00091-3 · Cited by 214
De Beer, E. L., Bottone, A. E., & Voest, E. E. (2001) · European Journal of Pharmacology · doi:10.1016/s0014-2999(01)00765-8 · Cited by 185
Hydrogels for combination delivery of antineoplastic agents
Bouhadir, K. H., Alsberg, E., & Mooney, D. J. (2001) · Biomaterials · doi:10.1016/s0142-9612(01)00003-5 · Cited by 168
Further evidence to support the melanocytic origin of MDA-MB-435
Ellison, G. (2002) · Molecular Pathology · doi:10.1136/mp.55.5.294 · Cited by 164
A phase I clinical trial and pharmacokinetic evaluation of liposome-encapsulated doxorubicin.
Rahman, A., Treat, J., Roh, J. K., Potkul, L., Alvord, W. G., Forst, D. A., & Woolley, P. V. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.6.1093 · Cited by 157
Rowinsky, E. K., Smith, L., Wang, Y. M., Chaturvedi, P. R., Villalona, M. A., Campbell, E., Aylesworth, C., Eckhardt, S. G., Hammond, L. A., Kraynak, M. A., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.9.2964 · Cited by 146
Gerrard, G., Payne, E. M., Baker, R. J., Jones, D. T., Potter, M. N., Prentice, H. G., Ethell, M. E., McCullough, H., Burgess, M. A., Mehta, A. B., et al. (2004) · PubMed · Cited by 95
Multidrug resistance proteins and other drug transport-related resistance to natural product agents
Broxterman, H. J., Giaccone, G., & Lankelma, J. (1995) · Current Opinion in Oncology · doi:10.1097/00001622-199511000-00011 · Cited by 84
Diestra, J. E., Condom, E., del Muro, X. G., Scheffer, G. L., Pérez-Piteira, J., Zurita, A. J., MUÑOZ-SEGUÍ, J., Vigués, F., Scheper, R. J., Capellá, G., et al. (2003) · The Journal of Urology · doi:10.1097/01.ju.0000074710.96154.c9 · Cited by 81
Farnesyltransferase inhibitors as anticancer agents: critical crossroads.
Doll, R. J., Kirschmeier, P. T., & Bishop, W. R. (2004) · PubMed · Cited by 80
Rao, U. S. M., & Scarborough, G. A. (1994) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)10165-x · Cited by 78
Meschini, S., Molinari, A., Calcabrini, A., Citro, G., & Arancia, G. (1994) · Journal of Microscopy · doi:10.1111/j.1365-2818.1994.tb03516.x · Cited by 49
Energy Dependent Transport of Xenobiotics and Its Relevance to Multidrug Resistance
Sharma, R., Awasthi, S., Yang, Y., Sharma, A., Singhal, S. S., & Awasthi, S. (2003) · Current Cancer Drug Targets · doi:10.2174/1568009033482047 · Cited by 40
Jabbour, E. J., Kantarjian, H. M., & Cortes, J. E. (2004) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190412331272677 · Cited by 30
Cited by
Immunogenic cell death and DAMPs in cancer therapy
Krysko, D. V., Garg, A. D., Kaczmarek, A., Krysko, O., Agostinis, P., & Vandenabeele, P. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3380 · Cited by 3,223
Multimodal immunogenic cancer cell death as a consequence of anticancer cytotoxic treatments
Inoue, H., & Tani, K. (2014) · Cell Death & Differentiation · doi:10.1038/cdd.2013.84 · Cited by 347
Exploiting evolutionary principles to prolong tumor control in preclinical models of breast cancer
Enriquez-Navas, P. M., Kam, Y., Das, T., Hassan, S., Silva, A., Foroutan, P., Ruiz, E., Martinez, G., Minton, S., Gillies, R. J., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad7842 · Cited by 322
Nanotechnology applied to overcome tumor drug resistance
Gao, Z., Zhang, L., & Sun, Y. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.05.051 · Cited by 303
Doxorubicin loaded iron oxide nanoparticles overcome multidrug resistance in cancer in vitro
Kievit, F. M., Wang, F. Y., Fang, C., Mok, H., Wang, K., Silber, J. R., Ellenbogen, R. G., & Zhang, M. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.01.024 · Cited by 289
Metadata
- Authors
- Shen, F., Chu, S., Bence, A. K., Bailey, B., Xue, X., Erickson, P. A., Montrose, M. H., Beck, W. T., & Erickson, L. C.
- Venue
- The Journal of Pharmacology and Experimental Therapeutics
- Publisher
- Elsevier BV
- Published
- 2008-01
- Volume
- 324
- Issue
- 1
- Pages
- 95-102
- ISSN
- 0022-3565 (ISSN-L)
- OpenAlex
- W2122754213
- Cited by
- 263
- References
- 21
- FWCI
- 3.32
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.